Abstract
Arzoxifene is a benzothiophene second-generation selective estrogen receptor modulator (SERM) under development by Eli Lilly & Co as a potential treatment for cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 880-885 |
| Number of pages | 6 |
| Journal | IDrugs |
| Volume | 6 |
| Issue number | 9 |
| State | Published - Sep 1 2003 |
ASJC Scopus subject areas
- Pharmacology